4S CAR-T CD20
Showing 1 - 25 of >10,000
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
- +4 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Sep 22, 2022
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5
Completed
- Lymphoma, Non-Hodgkin
- +3 more
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & Medical College of Wisconsin
Jun 26, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- CAR-T Autologous T cell injection
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Dec 2, 2022
B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)
Recruiting
- B Cell Non-Hodgkin's Lymphoma
- CD19/CD20-directed CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 10, 2022
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Chemotherapy
- Cell infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 13, 2023
Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023
Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)
Recruiting
- Large B-cell Lymphoma
- mosunetuzumab
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 21, 2022
B-cell Lymphoma Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)
Completed
- B-cell Lymphoma
- CD19/CD20 Dual-CAR-T cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Mar 6, 2022
B-cell Leukemia Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)
Completed
- B-cell Leukemia
- CD19/CD20 Dual-CAR-T cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Mar 6, 2022
T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)
Recruiting
- T-cell Lymphoma
- T-cell Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- +7 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 5, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022
B-cell Non-Hodgkin's Lymphoma Trial in Beijing (CD19/CD20 Dual-CAR-T cells)
Suspended
- B-cell Non-Hodgkin's Lymphoma
- CD19/CD20 Dual-CAR-T cells
-
Beijing, Beijing, ChinaBeijing Tsinghua Changgung Hospital
Jan 29, 2022
Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing
Recruiting
- Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
- Decitabine-primed Tandem CD19/CD20 CAR T Cells
- Decitabine-primed Tandem CAR19/20 engineered T cells
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)
Recruiting
- Cancer Disease
- bi-4SCAR PSMA/CD70 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 25, 2022
Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)
Recruiting
- Cancer Disease
- bi-4SCAR GD2/CD70 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 25, 2022
Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)
Recruiting
- Malignant Disease
- bi-4SCAR GD2/CD56 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 25, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/70 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/22 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 21, 2022